Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
L1CAM
REST API REST API
Homo sapiens
L1CAM is differentially expressed in 261 experiments: 142 organism parts: brain, amygdala, ... (140 more);, 202 disease states: normal, colorectal adenocarcinoma, ... (200 more);, 82 cell types 430 cell lines 39 compound treatments and 72 other conditions.
Synonyms S10, HSAS1, CD171, MIC5, HSAS, MASA, SPG1
Orthologs ENSCING00000007077 (Ciona intestinalis)   L1cam (Mus musculus)   nadl1.2 (Danio rerio)   L1CAM (Bos taurus)   nadl1.1 (Danio rerio)   L1cam (Rattus norvegicus)   Nrg (Drosophila melanogaster)   l1cam (Xenopus laevis)   L1CAM (Canis familiaris)   (Compare orthologs)
Gene Ontology Term plasma membrane, protein binding, heterophilic cell-cell adhesion, homophilic cell adhesion, blood coagulation, membrane fraction, presynaptic membrane, cell differentiation, external side of plasma membrane, identical protein binding, cell adhesion, terminal button, axon guidance, multicellular organismal development, neuron projection development, cell surface receptor linked signaling pathway, protein self-association, cell death, chemotaxis, integrin binding, nervous system development, integral to membrane, cell surface, PDZ domain binding, positive regulation of cell-cell adhesion, cell-cell adhesion mediated by integrin, leukocyte migration, sialic acid binding, homotypic cell-cell adhesion, positive regulation of calcium-mediated signaling, leukocyte cell-cell adhesion
InterPro Term Ig_sub, Immunoglobulin, Ig-like, Ig_sub2, Ig_I-set, Fibronectin_type3
Gene-Disease Assocation CORPUS CALLOSUM, PARTIAL AGENESIS OF, X-LINKED, MASA SYNDROME, HYDROCEPHALUS DUE TO CONGENITAL STENOSIS OF AQUEDUCT OF SYLVIUS; HSAS, HIRSCHSPRUNG DISEASE, SUSCEPTIBILITY TO, 1; HSCR1
UniProt Accession Q86SE4, P32004, Q7Z3Z9, Q7Z2H2, Q7Z2F9, Q7Z2J0, Q7Z2I3, Q7Z2J9, Q7Z2J8, Q7Z2J6, E7EMY4, E7EPI4, E7EVM4, E9PHJ4, F5H1H0, F5H111, F5H025
Search EB-eye ENSG00000198910
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-803, E-GEOD-3526, E-MTAB-62, E-GEOD-18105, ... (26 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, E-GEOD-19397, ... (39 experiments)

Factor Value U/D Experiments
SW480
4
E-GEOD-18005, E-MEXP-1014, E-MTAB-37, E-GEOD-2509
AGS
2
E-GEOD-15460, E-MTAB-37
BT-474
2
E-GEOD-3529, E-GEOD-5823
BT20
2
E-MTAB-37, E-MTAB-62
HT1080
2
E-MTAB-37, E-GEOD-20089
MOLT4
2
E-MTAB-62, E-MTAB-37
424 more value(s).


Cell type

studied in E-TABM-40, E-GEOD-20193, E-GEOD-22373, E-GEOD-21668, E-GEOD-3920, ... (46 experiments)

Factor Value U/D Experiments
memory B cell
2
E-MEXP-2360, E-TABM-702
plasma cell
2
E-MEXP-2360, E-GEOD-6691
human foreskin fibroblast
2
E-GEOD-18265, E-GEOD-18147
stromal cell
2
E-MEXP-1327, E-GEOD-10797
mast cell
1
E-GEOD-3982
hematopoietic progenitor cells
1
E-MEXP-70
76 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-1577, E-GEOD-12254, E-MTAB-62, ... (50 experiments)

Factor Value U/D Experiments
colorectal adenocarcinoma
1
3
E-AFMX-5, E-MTAB-62, E-TABM-145, E-MTAB-37
acute lymphoblastic leukemia
2
E-MTAB-37, E-MTAB-62
acute promyelocytic leukemia
2
E-MTAB-62, E-GEOD-1729
colon carcinoma
2
E-MTAB-62, E-GEOD-3726
glioblastoma
2
E-GEOD-4290, E-MTAB-37
lung adenocarcinoma
2
E-MTAB-62, E-MEXP-231
196 more value(s).


Compound treatment

studied in E-GEOD-15205, E-GEOD-3720, E-GEOD-5824, E-GEOD-5099, E-GEOD-6462, ... (23 experiments)

Factor Value U/D Experiments
none
2
6
E-GEOD-5824, E-MEXP-1269, E-GEOD-4600, E-GEOD-412, E-GEOD-2803, ... (8 experiments)
4OH-tamoxifen
1
E-GEOD-2292
saline
1
E-GEOD-3026
vanadium pentoxide
1
E-GEOD-5339
2-(3,4,5-trimethoxy-phenylamino)-pyrrolo[2,3-d]pyrimidines
1
1
E-GEOD-6932
placebo
1
E-MEXP-1335
33 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-GEOD-1729

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, E-GEOD-16363, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-MEXP-1251, E-GEOD-21589, ... (6 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-MEXP-2359, E-GEOD-2666, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-2509, E-GEOD-22148, E-TABM-147, E-GEOD-21138 ... (5 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-GEOD-7011, E-GEOD-7578, E-GEOD-20847, E-MTAB-108, ... (7 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-17476, E-GEOD-21750, E-GEOD-3624, E-TABM-601, ... (8 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-5681, E-GEOD-12773, E-MEXP-1741

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-GEOD-20194, E-GEOD-16716

Individual
studied in E-MTAB-197, E-GEOD-5764, E-GEOD-1926, E-MEXP-1648, E-GEOD-16363, ... (25 experiments)

Infection
studied in E-GEOD-12108, E-GEOD-12254, E-GEOD-17400

Injury
studied in E-GEOD-19743

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Material type
studied in E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-19703, E-GEOD-21750, E-GEOD-1460, E-GEOD-17636, E-GEOD-4600 ... (5 experiments)

Population
studied in E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-1880, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

Qrt pcr ereg dct
studied in E-GEOD-5851

Replicate
studied in E-GEOD-10896, E-GEOD-17204

RNAi
studied in E-MEXP-2115, E-GEOD-1703, E-MEXP-1509, E-GEOD-1676, E-MEXP-101, ... (9 experiments)

Sample preparation
studied in E-GEOD-16728

Sampling time point
studied in E-GEOD-19743, E-MEXP-70

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-19069, E-GEOD-2466

Stimulation
studied in E-GEOD-20114, E-GEOD-23984

Strain or line
studied in E-TABM-125

Survival time
studied in E-GEOD-3494, E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-GEOD-2748

Treatment
studied in E-GEOD-16837, E-GEOD-19246, E-GEOD-19815

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4922

Tumor size
studied in E-GEOD-6532

Vehicle
studied in E-GEOD-5258

Processing time: 0.491 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM